ストックスクリーナーアプリを入手
0.2849
6.59%
-0.0201
アフターアワーズ：
.28
-0.0049
-1.72%
前日終値:
$0.305
開ける：
$0.306
24時間の取引高:
122.92K
Relative Volume:
0.59
時価総額：
$10.86M
収益：
-
当期純損益:
$-117.67M
株価収益率:
-0.0922
EPS:
-3.09
ネットキャッシュフロー:
$-101.06M
1週間 パフォーマンス:
-16.21%
1か月 パフォーマンス:
-30.63%
6か月 パフォーマンス:
-36.12%
1年 パフォーマンス:
-89.60%
1日の値動き範囲:
$0.2743
$0.3281
1週間の範囲:
$0.2743
$0.35
52週間の値動き範囲:
$0.2743
$3.67
Athira Pharma Inc Stock (ATHA) Company Profile
名前
Athira Pharma Inc
セクター
電話
(425) 620-8501
住所
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
ATHA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
0.2849 | 10.86M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-19 | ダウングレード | Mizuho | Outperform → Neutral |
| 2024-09-04 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-09-04 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | ダウングレード | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | 開始されました | Rodman & Renshaw | Buy |
| 2022-10-17 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | 開始されました | Mizuho | Buy |
| 2022-06-23 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | ダウングレード | Jefferies | Buy → Hold |
| 2022-06-23 | ダウングレード | Stifel | Buy → Hold |
| 2022-05-10 | 開始されました | BTIG Research | Buy |
| 2022-04-21 | 開始されました | Berenberg | Buy |
| 2021-12-15 | 開始されました | Goldman | Neutral |
| 2020-10-13 | 開始されました | Goldman | Buy |
| 2020-10-13 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-13 | 開始されました | Jefferies | Buy |
| 2020-10-13 | 開始されました | Stifel | Buy |
すべてを表示
Athira Pharma Inc (ATHA) 最新ニュース
Athira Pharma stock hits 52-week low at $0.3 amid steep decline - Investing.com Australia
What is ATHA’s price-to-sales ratio telling us about the company’s value? - US Post News
Athira Pharma: Hold Rating Amid Strategic Uncertainty and Resource Challenges - TipRanks
Athira Pharma stock hits 52-week low at $0.33 amid steep decline - Investing.com India
Athira Pharma stock hits 52-week low at $0.33 amid steep decline By Investing.com - Investing.com South Africa
Athira Pharma Stock Price, Quotes and Forecasts | NASDAQ:ATHA - Benzinga
Athira Pharma’s Strategic Focus on ATH-1105 Amidst Uncertainties: Hold Rating Maintained - TipRanks
Athira Pharma’s 2024 Financial Results and Pipeline Progress - MSN
Athira Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Athira Pharma, Inc. SEC 10-K Report - TradingView
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates - GlobeNewswire
Athira Pharma stock hits 52-week low at $0.41 amid steep decline - Investing.com Australia
Athira Pharma stock hits 52-week low at $0.41 amid steep decline By Investing.com - Investing.com South Africa
Athira Pharma Inc expected to post a loss of 44 cents a shareEarnings Preview - TradingView
ATHA INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Athira Pharma, Inc. - Marketscreener.com
Molecular Partners (NASDAQ:MOLN) versus Athira Pharma (NASDAQ:ATHA) Head to Head Review - Defense World
Athira Pharma (ATHA) Expected to Announce Earnings on Thursday - Defense World
Alterity stock jumps on data for lead drug (ATHA:NASDAQ) - Seeking Alpha
Can Athira Pharma (NASDAQ:ATHA) Afford To Invest In Growth? - Yahoo Finance
Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct - MSN
Insider Buyers Lose Additional US$78k As Athira Pharma Dips To US$21m - Simply Wall St
Keeping Fraud Out of Research: Government Grant Whistleblower Awarded Over $200,000 - The National Law Review
Will Athira Pharma See A Boost From LIFT-AD Trial Results In Alzheimer's Research? - RTTNews
Alzheimer’s Drugmaker Athira Shells Out $4 Million In DOJ Settlement - Being Patient
Athira to pay $4M to resolve research misconduct allegations - BioWorld Online
ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024 - MSN
Bothell's Athira Pharma to pay $4M to settle falsified research claims - The Business Journals
Biotech company agrees to pay $4 million to settle data falsification allegations - Retraction Watch
Athira Inks $4M FCA Deal Over Ex-CEO's Research Fraud - Law360
Athira Pharma Inc. Agrees to Pay $4M to Settle False Claims Act Allegations Related to Scientific Research - U.S. Politics Today
Athira Pharma to Pay $4 Million Over Alleged Research Misconduct - Marketscreener.com
Bothell pharma company to pay $4 million over falsified research claims - MSN
Athira Pharma Settles Claims of NIH Research Grant Misconduct - Bloomberg Law
Athira Pharma CEO sells shares worth $14,107 By Investing.com - Investing.com South Africa
Athira Pharma CEO sells shares worth $14,107 - Investing.com
Athira Pharma VP of Finance Sells Shares for $1,618 - Investing.com India
Athira Pharma VP of Finance Sells Shares for $1,618 By Investing.com - Investing.com Canada
JMP Securities Downgrades Athira Pharma (ATHA) - MSN
Athira Pharma Insider Ups Holding By 111% During Year - Yahoo Finance
Athira Pharma's SWOT analysis: stock faces challenges after trial setback - Investing.com India
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND - The Manila Times
Athira Pharma Inc (ATHA) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):